Abbott Will Grow Zemplar Sales With Oral Formulation, Pre-dialysis Use
Executive Summary
Abbott expects that an oral formulation of Zemplar (paricalcitol) could increase the chronic kidney disease agent's market ten-fold
You may also be interested in...
Sensipar Hypocalcemia Studies Are Key To Expanded Indication, Amgen Says
Long-term hypocalcemia safety studies will be necessary before Amgen gains approval of an expanded indication for the chronic kidney disease agent Sensipar
Genzyme Renagel Growth To Come From Medicare Rx, Kidney Disease Use
Genzyme expects results from a Phase IV Renagel outcomes study to bolster the phosphate binder's long-term growth prospects, Renal Division General Manager John Butler told investors Feb. 19
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011